About: Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
Creator	Rusconi, Stefano Conti, Federico Giacomelli, Andrea Sacco, Luigi
Source	Medline; PMC
abstract	covid:ddc43015fcc961fc8560e776ca20411d7bff78f2#abstract
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1016/j.ebiom.2020.102820
bibo:pmid	32512519
has license	cc-by-nc-nd
sha1sum (hex)	ddc43015fcc961fc8560e776ca20411d7bff78f2
schema:url	https://doi.org/10.1016/j.ebiom.2020.102820
resource representing a document's title	Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
has PubMed Central identifier	PMC7276508
has PubMed identifier	32512519
schema:publication	EBioMedicine
resource representing a document's body	covid:ddc43015fcc961fc8560e776ca20411d7bff78f2#body_text
is schema:about of	named entity 'drugs' named entity 'possibility' named entity 'patients' named entity 'fact' named entity 'metabolic' named entity 'PATIENTS' named entity 'HISTORICAL' named entity 'PERCENTAGE' named entity 'COMPOSED OF' named entity 'STRATEGIES' named entity 'AVOIDANCE' named entity 'MUTATIONS' named entity 'AVAILABILITY OF' named entity 'POTENTIAL' named entity 'POSSIBILITY' named entity 'EXPOSURE' named entity 'PRESENCE OF' named entity 'high' named entity 'effects' named entity 'reverse transcriptase' named entity 'triple' named entity 'initially' named entity 'strategy' named entity 'mantra' named entity 'antiretrovirals' named entity 'protease inhibitors' named entity 'Dolutegravir' named entity 'lamivudine' named entity 'maintenance regimen' named entity 'Gilead Sciences' named entity 'observational studies' named entity 'dolutegravir' named entity 'lamivudine' named entity 'metabolic' named entity 'mantra' named entity 'lamivudine' named entity 'proviral' named entity 'antiretroviral' named entity 'convenience sample' named entity 'selection bias' named entity 'first-line' named entity 'genotype' named entity 'people living with HIV' named entity 'virological' named entity 'reverse transcriptase inhibitors' named entity 'people living with HIV' named entity 'Mylan' named entity 'Gilead Sciences' named entity 'genotype' named entity 'drug combination' named entity 'proviral' named entity 'genotypic' named entity 'integrase inhibitor' named entity 'observational studies' named entity 'critical role' named entity 'latently infected' named entity 'integrase inhibitors' named entity 'lamivudine' named entity 'probability' named entity 'ViiV Healthcare' named entity 'Merck Sharp and Dohme' named entity 'lamivudine' named entity 'next-generation sequencing' named entity 'probability' named entity 'lamivudine' named entity 'lamivudine' named entity 'virological' named entity 'antiretroviral therapy' named entity 'lamivudine' named entity 'lamivudine' named entity 'lamivudine' named entity 'probability' named entity 'dolutegravir' named entity 'lamivudine' named entity 'virological' named entity 'virological' named entity 'virological' named entity 'reverse transcriptase'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software